China Biologic Products (CBPO) Tops Q4 EPS by 19c

China Biologic Products (NASDAQ: CBPO) reported Q4 EPS of $0.74, $0.19 better than the analyst estimate of $0.55. Revenue for the quarter came in at $68.3 million versus the consensus estimate of $66.77 million.

Financial Outlook

For the full year of 2016, the Company expects total sales to grow 21% to 23% in RMB terms and non-GAAP adjusted net income to grow 24% to 26% in RMB terms over 2015 financial results. This guidance does not factor in any potential foreign currency translation impact. The Company adopted an exchange rate of approximately RMB6.21 = $1.00 based on weighted average quarterly exchange rates in 2015 in translating 2015 financial results, and expects that the total sales and non-GAAP adjusted net income in USD terms in 2016 will be adversely affected by the foreign currency translation impact.

For earnings history and earnings-related data on China Biologic Products (CBPO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Dare Bioscience (DARE) Tops Q2 EPS by 11c
• zSpace, Inc. (ZSPC) Reports Q2 results